Phase 3 ITHACA Study Results: Latest Insights on Isatuximab presented from ASH 2022 discussed by Dr. Irene Ghobrial from Dana-Farber Cancer Institute
Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study
We presented in the American Society of Hematology (ASH). Several abstracts related to MGUS and smoldering multiple myeloma. Some of them about risk stratification, who should be treated for smoldering myeloma because we know that many people are diagnosed with MGUS and smoldering myeloma…
The study that we have conducted or we’re currently conducting is really a prospective trial. And what we’re trying to do is take patients who have shown to have a durable, deep response to treatment for their myeloma and who are on maintenance therapy and see if they are able to stop their treatment, and then what happens after…
This email was intended for physicians and researchers dedicated to oncology. If this is not your specialty just respond to this email and let us know which cancer category you would prefer to receive updates.
%20Email.png?width=600&upscale=true&name=What%20are%20your%20thoughts%3F%20(300%20%C3%97%20250%20px)%20Email.png)